Since this disease is progressive and the treatments available would only help alleviate the signs and symptoms of cardiomyopathy for a certain period, it is possible that the TTR silencer was effective for a limited period of time; however, after this period, the TTR silencer may have been no longer effective in silencing the TTR mRNA and reducing the number of amyloid deposits in the myocardium [19]. This evidence concerns the gene TTR and cardiomyopathy.